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Among Costa Ricans, CYP2C9*2 was also lower in the AM than 
in the CRM population (P < 0.05). Moreover, the frequency of 
CYP2C9*3 in the CRM, AM and AC groups was 3.6%, 2.1% and 
3.3%, respectively. CYP2C9*6 was not detected.
Conclusion: Present data support that the CYP2C9*2 frequency is 
lower in Amerindian populations than Caucasians, suggesting the 
importance of pharmacogenetic studies for optimizing drug dosages 
in different populations according to their ancestry.
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Introduction: The aim of this research was to study the preva-
lence of methylenetetrahydrofolate reductase (MTHFR) C677T 
gene polymorphismsand homocysteine concentration in male 
patients, European race, with mild to moderate essential hyper-
tension.
Patients (or Materials) and Methods: The investigations were per-
formed in 35 patients (mean age, 50.0 [5.9] years). All the patients 
had family history of essential hypertension. The higher prevalence 
of risk factors was revealed: smoking – 62.8% patients, overweight – 
71.4%, dyslipidemia – 48.6%. The following defeats of targets were 
diagnosed: left ventricular hypertrophy – 40% patients, ultrasonic 
signs of carotids atherosclerosis – 82.8% patients. To identify muta-
tions С677Т of a gene MTHFR polymerase chain reaction with the 
subsequent restriction amplifications was used.
Results: Genotypes by MTHFR were distributed as follows: homozy-
gotes C allele (СС genotype) was defined in 19 patients (55.9%); 
heterozygotes (СТ genotype) in 11 patients (32.3 %); homozygotes 
Т allele ( TT genotype) in 4 patients (11.8%). Homocysteine concen-
tration in patients with СС genotype was authentically lower than 
in patients with СT and TT genotype (11.34 [0.64] vs 15.33 [0.57] 
mkmol/L; P < 0.001).
Conclusion: Thus, in male patients, European race, with mild to 
moderate essential hypertension the prevalence of mutant allele T, 
determining the reduction of enzyme activity MTHFR, was 44.1%. 
The presence of mutant allele T was associated with a higher level of 
homocysteine concentration.
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Introduction: Raloxifene is a selective oestrogen receptor modulator 
commonly used for the treatment of postmenopausal osteoporosis. 
The drug is significantly associated with an increased risk of deep 
venous thrombosis and pulmonary embolism, probably because of 
its estrogenic effects on the coagulation and fibrinolytic systems. It is 
known that many drugs vary in potency and/or toxicity according to 
a dosing time. Because both the coagulation and fibrinolytic systems 
exhibit circadian rhythms, such adverse effects of raloxifene could be 
diminished by optimizing a dosing time. The aim of the present study 
was to investigate the effects of dosing time of raloxifene on markers 
of coagulation and fibrinolysis, as well as of bone metabolism.
Patients (or Materials) and Methods: Postmenopausal patients with 
osteoporosis were randomly allocated to 2 groups: 1 received 60-mg 
raloxifene once daily in the morning, whereas the other received 
60-mg raloxifene in the evening, for 12 months.
Results: In both groups, the activity of coagulation Factors IX and 
XII significantly increased after 12 months treatment compared with 
baseline. The activity of coagulation Factors II and V, and levels 
of markers of bone metabolism (ie, bone alkaline phosphatase and 
tartrate-resistant acid phosphatase 5b) decreased in both groups. 
The changes in these markers did not differ between the 2 groups. In 
contrast, the plasma concentration of plasminogen activator inhibi-
tor-1 increased in the patients with the morning dose but not in the 
patients with the evening dose.
Conclusion: Because the elevated concentration of plasminogen acti-
vator inhibitor-1 is shown to be associated with the risk of venous 
thromboembolism, these data suggest that the evening dose of ralox-
ifene is relatively safe dosage regimen.
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Introduction: Ponesimod is a selective sphingosine-1 phosphate 
(S1P1) receptor modulator currently in clinical development for 
multiple sclerosis and plaque psoriasis. Drug-induced prolongation 
of the QT interval can lead to torsades de pointes and sudden cardiac 
death. The aim of this study was to assess whether ponesimod has 
a negative QT/QTc effect as per ICH E14 guidance in a thorough 
QT/QTc study.
Patients (or Materials) and Methods: This was a single-center, dou-
ble-blind, placebo- and positive-controlled (400-mg moxifloxacin), 
parallel group with nested crossover, up-titration study in 116 healthy 
male and female subjects (58 subjects on ponesimod and 58 subjects 
on moxifloxacin/placebo). All subjects received placebo for ponesi-
mod on day –1. In treatment group A, ponesimod was administered 
orally once daily for 22 days (10 mg on days 2–4, 20 mg on days 5–7, 
40 mg on days 8–12, 60 mg on days 13–15, 80 mg on days 16–18, 
and 100 mg on days 19–23). In addition, subjects received placebo 
